Triple-agonist peptides are among the most closely watched compounds in metabolic research. GLP-3 RT — a retatrutide-class molecule — targets three receptors at once: GLP-1, GIP, and glucagon. This combination is the reason it features so prominently in current literature.
Why a Triple Agonist
Single-receptor GLP-1 analogues defined the first generation of incretin research. Dual agonists added GIP signalling. Triple agonists extend the model further by engaging the glucagon receptor, which in preclinical models is associated with increased energy expenditure alongside the appetite-signalling effects of the incretin axis.
What Researchers Analyse
- Receptor binding and activation profiles across the three target receptors.
- Stability of the peptide backbone under storage and assay conditions.
- Dose-response characteristics in validated cellular models.
- Comparative pharmacology against single- and dual-agonist reference compounds.
Handling Notes
Like most synthetic peptides of this class, GLP-3 RT is supplied lyophilized and reconstituted before analysis. Standard cold-chain practice applies: store powder vials refrigerated or frozen away from light, reconstitute gently, and avoid repeated freeze-thaw cycles.
Documentation
Every batch should be verified against its certificate of analysis, with HPLC purity and mass spectrometry identity confirmation. Aesthetic Labs publishes third-party lab reports for supplied batches on the Lab Results page.
Research Use Only
GLP-3 RT is a research compound intended strictly for laboratory use. It is not for human or veterinary use, and nothing here should be read as a statement of clinical benefit.